Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + lapatinib
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Docetaxel + lapatinib is a combination of two antineoplastic agents used primarily in the treatment of HER2-positive metastatic breast cancer. Docetaxel is a taxoid antineoplastic agent that promotes microtubule assembly and stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis in cancer cells. Lapatinib is a small molecule tyrosine kinase inhibitor that targets both epidermal growth factor receptor (EGFR/HER1/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2), blocking their intracellular phosphorylation domains to prevent downstream signaling involved in tumor cell proliferation and survival. The combination has been studied for its efficacy and tolerability, particularly in patients with advanced or metastatic HER2-positive breast cancer[1][4][6].
- Other names
- none
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + lapatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + lapatinib.